CTMX
CytomX Therapeutics, Inc.Company Information
- Company Name
- CytomX Therapeutics, Inc.
- CIK
- CIK0001501989
- Category
- Accelerated filer
- Ticker: Exchange
- CTMX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CTMX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-06-15
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 374,489
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 211,862,359
- Shares outstanding
- 218,939,423
- Ownership
- 96.77%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -4.75%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 17 | 29 | 13 | 34 | 49 | 48 | 38 | 41 | 43 | 36 | 17 | 26 | ||||||
| Available For Sale Securities Debt Securities Current | 313 | 318 | 124 | 109 | 109 | 32 | 63 | 77 | 94 | 114 | 157 | 168 | ||||||
| Restricted Cash Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 37 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 13 | 3 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 6 | 5 | 4 | 5 | 5 | 4 | 3 | 3 | 4 | 5 | 5 | ||||||
| Assets Current | 373 | 353 | 144 | 149 | 165 | 87 | 107 | 124 | 143 | 167 | 183 | 201 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Goodwill | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Restricted Cash Noncurrent | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 5 | 2 | 3 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 381 | 359 | 152 | 158 | 175 | 98 | 121 | 139 | 159 | 185 | 202 | 221 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | ||||||
| Accrued Liabilities Current | 12 | 12 | 14 | 12 | 12 | 11 | 12 | 17 | 14 | 14 | 18 | 21 | ||||||
| Operating Lease Liability Current | 1 | 3 | 4 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | ||||||
| Contract With Customer Liability Current | 24 | 18 | 27 | 22 | 22 | 33 | 67 | 96 | 124 | 124 | 132 | 124 | ||||||
| Liabilities Current | 40 | 34 | 47 | 41 | 39 | 50 | 86 | 119 | 143 | 145 | 156 | 147 | ||||||
| Contract With Customer Liability Noncurrent | 31 | 1 | 2 | 6 | 10 | 16 | 27 | 34 | 37 | 60 | 80 | 112 | ||||||
| Operating Lease Liability Noncurrent | 4 | - | 0 | 0 | 1 | 3 | 4 | 6 | 7 | 8 | 9 | 11 | ||||||
| Other Liabilities Noncurrent | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | ||||||
| Liabilities | 79 | 39 | 53 | 51 | 55 | 73 | 121 | 162 | 190 | 216 | 249 | 272 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,053 | 1,050 | 811 | 790 | 788 | 693 | 691 | 687 | 685 | 678 | 676 | 673 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -751 | -730 | -712 | -682 | -668 | -668 | -692 | -710 | -716 | -710 | -723 | -724 | ||||||
| Stockholders Equity | 302 | 320 | 99 | 107 | 120 | 25 | -0 | -23 | -31 | -32 | -47 | -51 | ||||||
| Liabilities And Stockholders Equity | 381 | 359 | 152 | 158 | 175 | 98 | 121 | 139 | 159 | 185 | 202 | 221 | ||||||
| Convertible Preferred Stock | - | - | 0 | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Shares Authorized | - | - | 300 | - | - | - | 150 | - | - | - | 150 | - | ||||||
| Common Stock Shares Issued | - | - | 170 | - | - | - | 80 | - | - | - | 67 | - | ||||||
| Shares Outstanding | - | - | 170 | - | - | - | 80 | - | - | - | 67 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCytomX Therapeutics, Inc. (CTMX) — SEC Financial Statements & Analysis
CytomX Therapeutics, Inc. (CTMX) is a pharmaceutical preparations company, incorporated in DE. CytomX Therapeutics, Inc. trades on Nasdaq as: CTMX. CytomX Therapeutics, Inc. (CTMX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, CytomX Therapeutics, Inc. carries a market cap of $821.02M, a P/E ratio of -9.93x, a P/B ratio of 2.72x, a P/S ratio of 44.86x, an enterprise value of $803.80M, and an EV/EBITDA multiple of -9.24x. On profitability, it posts an operating margin of -476.19%, a net margin of -451.62%, a Return on Equity (ROE) of -39.18%, a Return on Assets (ROA) of -29.72%, and a Return on Invested Capital (ROIC) of -48.57%. Per share, it reports EPS of $-0.38, diluted EPS of $-0.38, free cash flow per share of $-0.38, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -87.03% year-over-year, net income growth of -272.26% year-over-year, and EPS growth of -201.56% year-over-year. On the balance sheet, it maintains a current ratio of 9.36x, a quick ratio of 9.25x, working capital of $333.29M, a debt-to-equity ratio of 0.26x, a debt ratio of 0.21, free cash flow of $-82.74M (TTM), and net debt of $-17.22M. Figures sourced from SEC EDGAR.
- Market Cap
- $821.02M
- P/E TTM
- -9.93x
- EPS TTM
- $-0.38
- P/B TTM
- 2.72x
- ROE TTM
- -39.18%
- ROA TTM
- -29.72%
- Debt To Equity
- 0.26x
- Free Cash Flow TTM
- $-82.74M
- Net Revenue TTM Growth 1Y
- -87.03%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CytomX Therapeutics, Inc. in?
CytomX Therapeutics, Inc. (CTMX) operates in the Pharmaceutical Preparations industry.
What exchange does CTMX trade on?
CytomX Therapeutics, Inc. (CTMX) trades on the Nasdaq.
Where is CytomX Therapeutics, Inc. incorporated?
CytomX Therapeutics, Inc. is incorporated in DE.
When was CytomX Therapeutics, Inc. (CTMX)'s most recent SEC filing?
CytomX Therapeutics, Inc. (CTMX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is CTMX's market cap?
CytomX Therapeutics, Inc. (CTMX) has a market capitalization of $821.02M as of 2026-06-30.
What is CTMX's EPS (earnings per share)?
CytomX Therapeutics, Inc. (CTMX)'s trailing twelve month EPS is $-0.38 as of 2026-06-30.
What is CTMX's ROE (return on equity)?
CytomX Therapeutics, Inc. (CTMX)'s trailing twelve month Return on Equity (ROE) is -39.18% as of 2026-06-30.
What is CTMX's ROA (return on assets)?
CytomX Therapeutics, Inc. (CTMX)'s trailing twelve month Return on Assets (ROA) is -29.72% as of 2026-06-30.
What is CTMX's ROIC (return on invested capital)?
CytomX Therapeutics, Inc. (CTMX)'s trailing twelve month Return on Invested Capital (ROIC) is -48.57% as of 2026-06-30.
What is CTMX's EV/EBITDA?
CytomX Therapeutics, Inc. (CTMX)'s trailing twelve month EV/EBITDA is -9.24x as of 2026-06-30.